Chroma Medicine is a biotechnology company focused on discovering and developing therapies that harness the power of epigenetic mechanisms to treat diseases. Their approach involves targeting gene regulation to potentially cure a range of diseases at their source.

Chroma Medicine

Chroma Medicine is pioneering a new class of single-dose genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, revolutionizing the treatment of disease.
 
Epigenetics is nature’s central mechanism for gene regulation, governing cell phenotype and function by precisely controlling gene activity without changing the underlying DNA sequence. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma Medicine is working at the cutting edge of precision genomics, building an entirely new class of therapeutics to achieve unparalleled control of gene expression.
 
*Note: Be aware of fraudulent recruiting advertisements and scams: Potential candidates for employment at Chroma Medicine should be aware of job offer fraud scams perpetrated through the use of the internet and social media platforms. To learn more, please visit the Join Us page on our website.

Casdin Capital

Wellington Management

T. Rowe Price

Janus Henderson Investors

Omega Funds

Cormorant Asset Management

Sixth Street Partners

Mubadala Capital Ventures

Newpath Management

Alexandria Venture Investments

ARCH Venture Partners

Atlas Venture

DCVC Bio

During #AmericanHeartMonth this February, Chroma is committed to spreading awareness and encouraging daily proactive steps for #OurHearts. Studies show that just 30 minutes of daily exercise can significantly reduce your risk of a heart attack. 

We invite you to #LoveYourHeart and participate in a nearby #HeartWalk: https://lnkd.in/eYxZcHu

During today's Keystone Symposia on Precision Genome Engineering, Morgan Maeder, PhD, Senior Director of Payload Sciences, will present on the therapeutic development of #EpigeneticEditors, highlighting the potential of our approach for enabling treatment of serious diseases. Hope to see you there!

#KSGenomeEng24 
#EpigeneticEditing
#PrecisionGenomeEngineering
#Biotech

Join us next week at the Keystone Precision Genome Engineering conference where Morgan Maeder, PhD, Senior Director of Payload Sciences, will present on the development of therapeutic #EpigeneticEditors. Looking forward to connecting with colleagues and learning more about the latest breakthroughs in genomic medicine.
 
Register to attend: http://bit.ly/48sxD4w

#KSGenomeEng24
#PrecisionGenomeEngineering
#EpigeneticEditing
#Biotech

While many of us will enjoy a slow down next week, we are deeply grateful to our dedicated scientists who will keep key experiments running so we can continue to make advancements in #EpigeneticEditing in 2024.

Wishing you and your loved ones a cheerful and healthy holiday season and New Year! 

#HappyHolidays 

Cultivating curiosity and learning is central to Chroma’s culture. Through our partnership with Northeastern University’s co-op program, we provide students with meaningful experiences in cutting-edge biotech. Our second cohort did an outstanding job and recently presented their capstone poster projects to the entire Chroma team, highlighting their work over the past 6 months.

Thank you to our co-ops for all of your contributions, and best of luck in your classes and future endeavors!

#EpigeneticEditing
#Biotech
#CoOp
#Internship

COM:CHROMAMEDICINE

Chroma Medicine

locale

market

industry

website

crunchbase

linkedin

founding date

investor of

Metrics